{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:04:43Z","timestamp":1783631083796,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Covidien Japan Inc."},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Eli Lilly Japan K.K."},{"name":"Shionogi & Co., Ltd."},{"name":"Chugai Pharmaceutical Co., Ltd."},{"name":"Kyowa Kirin Co., Ltd."},{"name":"Taiho Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The prevalence of salvage surgeries after drug therapy for non-small cell lung cancer (NSCLC) has risen, mainly due to recent progress in molecular-targeted drugs and immune checkpoint inhibitors for NSCLC. While the safety and effectiveness of salvage surgery after drug therapy for NSCLC have been studied, its indications remain unclear. We aimed to identify the prognostic factors affecting survival in patients with advanced-stage (stages III\u2013IV) NSCLC treated with salvage surgery after drug therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective investigation was conducted on patients who received salvage surgery after drug therapy at four hospitals between 2007 and 2020. Salvage surgery was defined as surgery after drug therapy for local progression, tumor conversion to resectable status, and discontinuation of prior drug therapy owing to serious complications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-two patients received cytotoxic agents alone (<jats:italic>n<\/jats:italic> = 12 [38%]), tyrosine kinase inhibitors (TKIs; <jats:italic>n<\/jats:italic> = 16 [50%]), or immune checkpoint inhibitors (<jats:italic>n<\/jats:italic> = 4 [13%]) as prior drug therapy. In 11 (34%) and 21 (66%) patients, the clinical stage before treatment was III or IV, respectively. The median initial and preoperative serum carcinoembryonic antigen (CEA) levels were 10.2 (range, 0.5<jats:bold>\u2013<\/jats:bold>1024) ng\/mL and 4.2 (range, 0.6<jats:bold>\u2013<\/jats:bold>92.5) ng\/mL, respectively. Among the patients, 28 (88%) underwent lobectomy, 2 (6%) underwent segmentectomy, and 2 (6%) underwent wedge resection. Complete resection of the primary lesion was accomplished in 28 (88%) patients. Postoperative complications were documented in six (19%) patients. Mortality rates were 0% at 30 days and 3% at 90 days post-operation. The 5-year overall survival rate stood at 66%, while the 5-year progression-free survival rate was 21%. Multivariate analyses showed that prior TKI therapy and preoperative serum CEA level &lt; 5 ng\/mL were prognostic factors influencing overall survival (hazard ratio [95% confidence interval]: 0.06 [0.006<jats:bold>\u2013<\/jats:bold>0.68] and 0.03 [0.002<jats:bold>\u2013<\/jats:bold>0.41], respectively). The 5-year overall survival in the 11 patients with both favorable prognosticators was 100%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this study, prior TKI therapy and preoperative serum CEA level &lt; 5 ng\/mL were favorable prognostic factors for overall survival in patients with NSCLC treated with salvage surgery. Patients with these prognostic factors are considered good candidates for salvage surgery after drug therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-023-03177-5","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T04:02:02Z","timestamp":1694750522000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prognostic factors affecting survival in patients with non-small cell lung cancer treated with salvage surgery after drug therapy: a multi-institutional retrospective study"],"prefix":"10.1186","volume":"21","author":[{"given":"Shigeki","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Okui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sawafuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Shigenobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Masai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Kaseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Hishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Asamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"3177_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hed.20309","volume":"28","author":"IM Agra","year":"2006","unstructured":"Agra IM, Carvalho AL, Ulbrich FS, de Campos OD, Martins EP, Magrin J, et al. Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck. 2006;28:107\u201313.","journal-title":"Head Neck"},{"key":"3177_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jtcvs.2008.05.016","volume":"137","author":"Y Tachimori","year":"2009","unstructured":"Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, Kato H. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2009;137:49\u201354.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3177_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1006\/gyno.1994.1242","volume":"55","author":"RL Coleman","year":"1994","unstructured":"Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ, Rutledge FN. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol. 1994;55:29\u201335.","journal-title":"Gynecol Oncol."},{"key":"3177_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0022-5223(19)36752-2","volume":"101","author":"FA Shepherd","year":"1991","unstructured":"Shepherd FA, Ginsberg R, Patterson GA, Feld R, Goss PE, Pearson FG, et al. Is there ever a role for salvage operations in limited small-cell lung cancer? J Thorac Cardiovasc Surg. 1991;101:196\u2013200.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3177_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.athoracsur.2020.10.035","volume":"112","author":"K Shimizu","year":"2021","unstructured":"Shimizu K, Ohtaki Y, Suzuki K, Date H, Yamashita M, Iizasa T, et al. Salvage surgery for non-small cell lung cancer after definitive radiotherapy. Ann Thorac Surg. 2021;112:862\u201373.","journal-title":"Ann Thorac Surg"},{"key":"3177_CR6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.21037\/tlcr-20-453","volume":"10","author":"A Hamada","year":"2021","unstructured":"Hamada A, Soh J, Mitsudomi T. Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer. Transl Lung Cancer Res. 2021;10:555\u201362.","journal-title":"Transl Lung Cancer Res"},{"key":"3177_CR7","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.athoracsur.2019.06.087","volume":"108","author":"M Sonobe","year":"2019","unstructured":"Sonobe M, Yutaka Y, Nakajima D, Hamaji M, Menju T, Ohsumi A, et al. Salvage surgery after chemotherapy or chemoradiotherapy for initially unresectable lung carcinoma. Ann Thorac Surg. 2019;108:1664\u201370.","journal-title":"Ann Thorac Surg"},{"key":"3177_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.lungcan.2020.04.013","volume":"145","author":"AK Kobayashi","year":"2020","unstructured":"Kobayashi AK, Horinouchi H, Nakayama Y, Ohe Y, Yotsukura M, Uchida S, et al. Salvage surgery after chemotherapy and\/or radiotherapy including SBRT and proton therapy: a consecutive analysis of 38 patients. Lung Cancer. 2020;145:105\u201310.","journal-title":"Lung Cancer"},{"key":"3177_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2020.12.037","volume":"153","author":"Y Ohtaki","year":"2021","unstructured":"Ohtaki Y, Shimizu K, Suzuki H, Suzuki K, Tsuboi M, Mitsudomi T, et al. Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. Lung Cancer. 2021;153:108\u201316.","journal-title":"Lung Cancer"},{"key":"3177_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s11748-022-01808-4","volume":"70","author":"S Suzuki","year":"2022","unstructured":"Suzuki S, Asakura K, Okui M, Sawafuji M, Shigenobu T, Tajima A, et al. Safety and efficacy of salvage surgery for non-small cell lung cancer: a retrospective study of 46 patients from four Keio-affiliated hospitals. Gen Thorac Cardiovasc Surg. 2022;70:891\u20139.","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"3177_CR11","first-page":"611","volume":"1","author":"S Burdett","year":"2006","unstructured":"Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol. 2006;1:611\u201321.","journal-title":"J Thorac Oncol"},{"key":"3177_CR12","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","volume":"383","author":"NSCLC Meta-analysis Collaborative Group","year":"2014","unstructured":"NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561\u201371.","journal-title":"Lancet"},{"key":"3177_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.","journal-title":"Ann Surg"},{"key":"3177_CR14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11748-014-0508-5","volume":"64","author":"T Hishida","year":"2016","unstructured":"Hishida T, Yoshida J, Aokage K, Nagai K, Tsuboi M. Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases. Gen Thorac Cardiovasc Surg. 2016;64:429\u201333.","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"3177_CR15","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/1759-7714.13366","volume":"11","author":"W Song","year":"2020","unstructured":"Song W, Di S, Liu J, Fan B, Zhao J, Zhou S, et al. Salvage surgery for advanced non-small cell lung cancer after targeted therapy: a case series. Thorac Cancer. 2020;11:1061\u20137.","journal-title":"Thorac Cancer"},{"key":"3177_CR16","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1111\/1759-7714.14044","volume":"12","author":"K Li","year":"2021","unstructured":"Li K, Cao X, Ai B, Xiao H, Huang Q, Zhang Z, et al. Salvage surgery following downstaging of advanced non-small cell lung cancer by targeted therapy. Thorac Cancer. 2021;12:2161\u20139.","journal-title":"Thorac Cancer"},{"key":"3177_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.athoracsur.2018.02.030","volume":"106","author":"MJ Bott","year":"2018","unstructured":"Bott MJ, Cools-Lartigue JC, Tan KS, Dycoco J, Bains MS, Downey RJ, et al. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg. 2018;106:178\u201383.","journal-title":"Ann Thorac Surg"},{"key":"3177_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/s-0041-1730968","volume":"70","author":"L Bertolaccini","year":"2022","unstructured":"Bertolaccini L, Galetta D, Sedda G, de Marinis F, Spaggiari L. Safety analysis of salvage surgery for advanced stages or metastatic lung cancers. Thorac Cardiovasc Surg. 2022;70:273\u20136.","journal-title":"Thorac Cardiovasc Surg"},{"key":"3177_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/jso.26691","volume":"125","author":"A Smith","year":"2022","unstructured":"Smith A, Wali A, Montes A, Hadaki M, Harrison-Phipps KH, Karapanagiotou EM, et al. Salvage pulmonary resection in stages III b-IV lung cancer after treatment with immune checkpoint inhibitors case series and literature review. J Surg Oncol. 2022;125:290\u20138.","journal-title":"J Surg Oncol"},{"key":"3177_CR20","first-page":"185","volume":"71","author":"T Shimoyama","year":"2018","unstructured":"Shimoyama T, Kimura B. Salvage surgery after radical chemotherapy for N3 non-small cell lung cancer. Kyobu Geka. 2018;71:185-9 Japanese.","journal-title":"Kyobu Geka."},{"key":"3177_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/1759-7714.12423","volume":"8","author":"H Hino","year":"2017","unstructured":"Hino H, Nishimura T, Usuki C, Sazuka M, Ito T, Seki A, et al. Salvage surgery for primary lung cancer after chemotherapy in octogenarians. Thorac Cancer. 2017;8:271\u20134.","journal-title":"Thorac Cancer"},{"key":"3177_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","volume":"19","author":"WZ Zhong","year":"2018","unstructured":"Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1\u2013N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19:139\u201348.","journal-title":"Lancet Oncol"},{"key":"3177_CR23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/COC.0000000000000533","volume":"42","author":"J Raphael","year":"2019","unstructured":"Raphael J, Vincent M, Boldt G, Shah PS, Rodrigues G, Blanchette P. Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) in resected non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Am J Clin Oncol. 2019;42:440\u20135.","journal-title":"Am J Clin Oncol"},{"key":"3177_CR24","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711\u201323.","journal-title":"N Engl J Med"},{"key":"3177_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jtho.2016.10.012","volume":"12","author":"C Kim","year":"2017","unstructured":"Kim C, Hoang CD, Kesarwala AH, Schrump DS, Guha U, Rajan A. Role of local ablative therapy in patients with oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Oncol. 2017;12:179\u201393.","journal-title":"J Thorac Oncol"},{"key":"3177_CR26","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.cllc.2018.09.010","volume":"20","author":"F Hu","year":"2019","unstructured":"Hu F, Xu J, Zhang B, Li C, Nie W, Gu P, et al. Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations. Clin Lung Cancer. 2019;20:e81\u201390.","journal-title":"Clin Lung Cancer"},{"key":"3177_CR27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cllc.2020.04.004","volume":"21","author":"XY Li","year":"2020","unstructured":"Li XY, Zhu XR, Zhang CC, Yu W, Zhang B, Shen TL, et al. Analysis of progression patterns and failure sites of patients with metastatic lung adenocarcinoma with EGFR mutations receiving first-line treatment of tyrosine kinase inhibitors. Clin Lung Cancer. 2020;21:534\u201344.","journal-title":"Clin Lung Cancer"},{"key":"3177_CR28","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","volume":"17","author":"DR Gomez","year":"2016","unstructured":"Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672\u201382.","journal-title":"Lancet Oncol"},{"key":"3177_CR29","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37:1558\u201365.","journal-title":"J Clin Oncol."},{"key":"3177_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.lungcan.2011.11.012","volume":"76","author":"M Grunnet","year":"2012","unstructured":"Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76:138\u201343.","journal-title":"Lung Cancer"},{"key":"3177_CR31","doi-asserted-by":"publisher","first-page":"686313","DOI":"10.3389\/fmolb.2021.686313","volume":"8","author":"Z Jiao","year":"2021","unstructured":"Jiao Z, Cao S, Li J, Hu N, Gong Y, Wang L, et al. Clinical associations of preoperative and postoperative serum CEA and lung cancer outcome. Front Mol Biosci. 2021;8:686313.","journal-title":"Front Mol Biosci"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-023-03177-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-023-03177-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-023-03177-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T02:13:15Z","timestamp":1700619195000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-023-03177-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3177"],"URL":"https:\/\/doi.org\/10.1186\/s12957-023-03177-5","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Keio University School of Medicine (approval no. 20200092) and the ethical committees of the other three participating Keio University-affiliated hospitals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The need for informed consent for publication was waived according to the policy of our IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors KA, NO, KM, KK, TH, and HA have declared competing interests, having received unrestricted institutional funds from several companies including the following: Chugai Pharmaceutical Co., Ltd.; Covidien Japan Inc.; Daiichi Sankyo Co., Ltd.; Eli Lilly Japan K.K.; Kyowa Kirin Co., Ltd.; Shionogi & Co., Ltd.; and Taiho Pharmaceutical Co., Ltd. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"290"}}